Fig. 7
Ad5-Ki67/IL-15 induced potent antitumor efficacy in GBM model with GA-MSCs. A BALB/nu-c mice were subcutaneously injected with 100 μl PBS suspension containing 1 × 106 U87-Luc cells and divided into groups according to tumor growth conditions based on live-animal IVIS imaging 14 days post tumor cell injection. Subsequently, the 100 μl GA-MSCs suspension (1 × 105 cells) or Ad5-Ki67/IL-15 (3 × 1011 vp) plus GA-MSCs (1 × 105 cells) were injected into the tumor sites. IVIS imaging was also performed 3 and 6 days post virus injection. B and C Representative mice from xenograft experiments in which U87 cells with GA-MSCs (upper) or U87 cells with GA-MSCs plus OV (lower) were injected into the right underarm of nude mice. Obviously, the sizes of the GA-MSCs plus OV group tumors were lower than those of their GA-MSCs counterparts. *P < 0.05. D The tumor specimens were acquired to evaluate PD-L1 expression. The images of blots were cropped from different gels; moreover, exposure time of β-actin and PD-L1 was, respectively, 15 s and 45 s. Western blotting confirmed PD-L1 in GA-MSC plus virus was reduced compared to the GA-MSCs group